Free Trial

Seres Therapeutics Q2 2024 Earnings Report

Seres Therapeutics logo
$0.72 -0.03 (-4.53%)
As of 03/28/2025 04:00 PM Eastern

Seres Therapeutics EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.08
One Year Ago EPS
$0.36

Seres Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Seres Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Remove Ads

Seres Therapeutics Earnings Headlines

A brutally honest economic warning for 2025 (see proof)
New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....
Seres Therapeutics (MCRB) Gets a Hold from Piper Sandler
Seres Therapeutics reports FY24 EPS (81c), consensus (20c)
See More Seres Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Seres Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seres Therapeutics and other key companies, straight to your email.

About Seres Therapeutics

Seres Therapeutics (NASDAQ:MCRB), a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

View Seres Therapeutics Profile

More Earnings Resources from MarketBeat